Clinical trial · Interventional
Low Dose Metronomic Poly-chemotherapy for Metastatic CRC
Metronomic Poly-chemotherapy for Metastatic Colorectal Cancer at Progression Following Established Treatments: Clinical and Laboratory Research
NCT02280694CI-TRIAL-00043369LDMchemoCRCcompletedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study investigates the activity of a new regimen of treatment for patients with metastatic colorectal carcinoma. This includes a combination of well-known chemotherapy agents and anti-inflammatory agents, when administered orally at low daily doses and without planed brakes (Low Dose Metronomic regimen), in contrast with the conventional and already exhausted regimens of treatment at Maximal Tolerated Doses (MTD) which required pre-planned brakes between treatment days.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Capecitabine | Drug | Capecitabine | ALIAS |
| Celecoxib | Drug | Celecoxib | ALIAS |
| Cyclophosphamide | Drug | Cyclophosphamide | ALIAS |
| Methotrexate | Drug | Methotrexate | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- capecitabine, cyclophosphamide, methotrexate, celecoxib
- description
- The Investigational Product: Route and Dosage Form Ambulatory/oral, continuous but not uniform, DAILY treatment 1. Tab. CYCLOPHOSPHAMIDE 50mg, 1X1/day ONLY days 1-5 / week; At evening only (at the end of meal) 2. Tab. CAPECITABINE 500mg, fixed dose of 1500mg/day (1000mg at morning + 500mg at evening) ONLY on days 1-5 / week; At morning AND at evening (at the end of meals) 3. Tab. METHOTREXATE 2.5mg, 1x2/day ONLY on days 6-7/week; At morning AND evening (one hour before meal) 4. Tab. CELECOXIB 200 mg, 1x2/day EVERY day (at the end of meal)
- interventionNames
- Drug: Capecitabine
- Drug: Cyclophosphamide
- Drug: Methotrexate
- Drug: Celecoxib
Primary outcomes (1)
- measure
- The median progression free survival (mPFS)
- timeFrame
- Base line and every consecutive 8 weeks, up to disease progression or exit from study for any other cause, up to 18 months.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 85 Years
Show eligibility criteria text
Inclusion Criteria: 1. Histological (or cytological) proof of colorectal carcinoma (CRC) 2. Measurable metastases 3. ECOG (Eastern Cooperative Oncology Group) performance status 0-2 4. Progressing disease following all available chemotherapy treatment lines (including chemotherapy, bevacizumab+/-ziv-aflibercept, and an epidermal growth factor receptor (EGFR) inhibitor \[if WT(wild type)-KRAS\] 5. The central-radiologist's confirmation of PD\* under the last (previous) line of "conventional treatment". \* PD (progressive disease) by RECIST(Response Evaluation Criteria in Solid Tumors) criteria : a) there is 20% or more relative increment in the sum of diameters of target lesions in comparison with the base line sum, and their absolute increase is 5 mm. or more, or b) there appeared one or more new lesions, or c)there is substantial worsening in non-target disease 6. Age: between 18 and 85 7. Prior radiotherapy either as adjuvant treatment or for palliation is allowed, unless this was delivered to the only measurable lesion 8. Complete blood count reflecting adequate Bone Marrow: Hb=/ \> 9 g/dL, ANC=/\> 1,500 Plt =/\> 75,000/mcL; 9. Adequate liver function: 1. Total Bilirubin always =/\<X1.5 ULN 2. ALT and AST and Alkaline Phosphatase =/ \< 2.5 X upper normal limit , although in patients with liver metastases these are acceptable if =/\< 5 X ULN; 11. Adequate renal function (serum creatinine): =/\< 1.5 X ULN. 12. Absence of any non-hematological toxicity at grade 2 or higher. 13.The patient is able to understand and ready to sign the informed consent Exclusion Criteria: 1. Lack of confirmation of PD (under the pre-study treatment) by the central radiologist 2. Any concurrent other active cancer (except basal cell or squamous cell carcinoma of skin and early prostate cancer or DCIS- in situ breast cancer) 3. Inability to adhere to monthly visits to the oncological unit for evaluation 4. Presence of brain metastases 5. Continuous treatment with steroids or with NSAIDs or with anticoagulants during the last year (except micropirin) 6. Previous radiotherapy to the only site of measurable disease 7. Existence of active peptic ulcer or symptomatic coronary disease 8. Existence of chronic inflammatory diseases, such as ulcerative colitis or Crohn's disease or rheumatoid arthritis 9. Presence of ascites, and/or any other "third space" finding (eg. significant leg edema)
References
Publications (1)
- BACKGROUNDVon Hoff DD, Stephenson JJ Jr, Rosen P, Loesch DM, Borad MJ, Anthony S, Jameson G, Brown S, Cantafio N, Richards DA, Fitch TR, Wasserman E, Fernandez C, Green S, Sutherland W, Bittner M, Alarcon A, Mallery D, Penny R. Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol. 2010 Nov 20;28(33):4877-83. doi: 10.1200/JCO.2009.26.5983. Epub 2010 Oct 4. PMID 20921468